Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Clinical Trial of PXD101 in Patients With T-Cell Lymphomas

Study:

A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas

Rationale:

n/a

Purpose:

This is an open-label, non-randomized trial to assess the effectiveness of PXD101 in patients with recurrent or refractory cutaneous or peripheral and other types of T-cell lymphomas. PXD101 is a new, potent histone deacetylase (HDAC) inhibitor. Patients are treated with belinostat(PXD101) 1000 mg/m2 on days 1-5 of a 21 day cycle.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Cutaneous T-Cell Lymphoma
Peripheral T-Cell Lymphoma
Non-Hodgkin`s Lymphoma		 Drug: belinostat Phase 2

Verified by TopoTarget A/S December, 2012

Sponsored by: TopoTarget A/S
Information provided by: TopoTarget A/S
ClinicalTrials.gov identifier: NCT00274651

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.